CollPlant Biotechnologies’ (CLGN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a report issued on Friday,Benzinga reports. They currently have a $11.00 price target on the stock.

CLGN has been the topic of a number of other reports. EF Hutton Acquisition Co. I upgraded shares of CollPlant Biotechnologies to a “strong-buy” rating in a research report on Monday, August 5th. D. Boral Capital reiterated a “buy” rating and set a $14.00 price objective on shares of CollPlant Biotechnologies in a research note on Wednesday, November 27th.

CollPlant Biotechnologies Stock Performance

Shares of CLGN opened at $4.48 on Friday. CollPlant Biotechnologies has a one year low of $3.31 and a one year high of $6.99. The stock’s fifty day moving average is $4.29 and its 200-day moving average is $4.81. The firm has a market capitalization of $51.30 million, a price-to-earnings ratio of -2.91 and a beta of 0.44.

Institutional Investors Weigh In On CollPlant Biotechnologies

Several hedge funds and other institutional investors have recently bought and sold shares of CLGN. Benjamin Edwards Inc. bought a new position in shares of CollPlant Biotechnologies during the 3rd quarter valued at about $112,000. Villere ST Denis J & Co. LLC boosted its holdings in CollPlant Biotechnologies by 24.4% during the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock worth $2,407,000 after buying an additional 95,000 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its position in CollPlant Biotechnologies by 6.4% in the second quarter. Pinnacle Associates Ltd. now owns 564,360 shares of the company’s stock worth $2,805,000 after buying an additional 33,905 shares during the last quarter. 21.69% of the stock is currently owned by institutional investors.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.